艾司西酞普兰用于妊娠期抑郁的安全性研究探讨  

Research progress on the safety and effectiveness of escitalopram in the treatment of pregnant women with depression

作　　者：王思捷[1] 张峻[1] 李骞[1] 黄桦[1] 王晶晶[1] 周琼[1] 姚勤[1] WANG Sijie;ZHANG Jun;LI Qian;HUANG Hua;WANG Jingjing;ZHOU Qiong;YAO Qin(Department of Clinical Pharmacy,the First Affiliated Hospital of Kunming Medical University,Kunming 650032,Yunnan,China)

机构地区：[1]昆明医科大学第一附属医院临床药学科

出　　处：《中国临床药理学与治疗学》2019年第9期1070-1074,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：云南省教育厅科学研究基金项目(2017zDX166);云南省卫生科技计划项目(2017NS069、2017NS070);云南省高层次卫生计生技术人才培养专项经费资助(L-201614、H-2017050、H-2017051、H-2017053);云南省科技厅-昆明医科大学应用基础研究联合专项重点项目(2018FE001(-167))

摘　　要：选择性5-羟色胺再摄取抑制剂在临床应用中已成为一线抗抑郁药,其中艾司西酞普兰在临床被广泛用于治疗抑郁症,并取得了良好的治疗效果。但对于妊娠期抑郁症的患者,其妊娠期间使用艾司西酞普兰的资料有限。本文对艾司西酞普兰在妊娠期抑郁症患者中应用的安全性进行探讨。5-hydroxytryptamine reuptake inhibitor(SSRIs)has become a first-line anti-depressant in clinic,among which escitalopram is widely used in the treatment of major depression,and has achieved good therapeutic effect.However,for patients with gestational depression,the safety of using escitalopram during pregnancy is still uncertain.The safety and effectiveness of escitalopram in patients with gestational depression was reviewed in this paper.

关 键 词：艾司西酞普兰 抑郁 妊娠 安全性 

分 类 号：R749[医药卫生—神经病学与精神病学]